NEW: No-Cost Streetwise Live! Events. This type of intellectual capital is usually not made available to the general public. Learn More
News Update

Telemedicine Firm Continues Expansion by Acquiring Majority Interest in Ontario Medical Clinic

News Update
  ()
The clinic will be integrated into the CloudMD EMR platform. read more >
News Update

Canadian Biotech Advances Antibodies, Diagnostics Programs in Q2/20

News Update
  ()
One highlight is ProMIS Neurosciences' development of a SARS CoV-2 antibody test. read more >

Mesoblast Shares Rocket Higher as FDA Committee Votes in Favor of Remestemcel-L for Pediatric SR-aGVHD Patients

  ()
Shares of Mesoblast Ltd. traded 50% higher after the company reported that the U.S. FDA's Oncologic Drugs Advisory Committee voted nine to one in favor of remestemcel-L (RYONCIL™) for efficacy in children with steroid-refractory acute graft versus host disease. read more >

Pennant Group Shares Fly 40% Higher on Q2 Earnings and Raised FY Adjusted EPS Guidance

  ()
Shares of The Pennant Group reached a new 52-week high after the company reported a 12.1% increase in Q2/20 revenue and raised FY/20 adjusted EPS guidance by 34.2%. read more >
News Update

Biotech Develops Oral Film Strips for Psychedelic Medicine Delivery

News Update
  ()
This development is a technical milestone for Revive Therapeutics and its drug delivery technology. read more >

Eyenovia Shares Look 38% Higher on Development Deal with Arctic Vision in Asia

  ()
Shares of Eyenovia Inc. set a new 52-week high after the firm reported it entered into an exclusive collaboration and license agreement with Arctic Vision to develop and market MicroPine and MicroLine in China and South Korea. read more >

$18.5 Billion Merger Could Mean Big Gains for These Five Tiny Telemedicine Stocks

Contributed Opinion
  ()
Independent financial analyst Matt Badiali examines five small companies poised to profit as digital health becomes mainstream during the coronavirus pandemic. read more >

Is Summit's Ridinilazole a Threat to Acurx's Ibezapolstat in the C.difficile Space?

Contributed Opinion
  ()
Dr. KSS, the founder and editor-in-chief of BioPub.co, compares the two drugs as potential treatments for C. difficile. read more >

Seres Therapeutics Shares Go Parabolic on Positive Topline Data from Phase 3 C.Diff Trial

  ()
Seres Therapeutics shares traded 350% higher setting a new 52-week high after the firm reported positive topline results from its SER-109 Phase 3 ECOSPOR III study in recurrent C. difficile infection. read more >
News Update

Pharmaceutical Firm Doses First Patient in Phase 2 IPF and Chronic Cough Trial

News Update
  ()
Algernon Pharmaceuticals reported that the first patient has been dosed in the Phase 2 human study of Ifenprodil for treatment of idiopathic pulmonary fibrosis and chronic cough. read more >

Expert Investing Ideas

"SPR is the number one cannabis stock to own today."

–Cynthia Berryman, Financial News Now


"We expect PMN to forge a licensing deal in Q2/19 or Q3/19."

–André Uddin, Mackie Research Capital


"I'm excited about the new team Sproutly is bringing on."

–Jimmy Mengel, Marijuana Minifesto


"VIV signed a partnership with CSA Animal Nutrition."

–Alex Koyfman, Penny Stock Millionaire


Learn More about Streetwise Reports Live

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical
News Update

Biopharma Preparing to Initiate Phase 3 COVID-19 Trial

News Update
  ()
Revive Therapeutics is now "finalizing agreements and aligning resources to initiate the Phase 3 clinical trial in September." read more >

Denali Shares Rise 37% on Advancement of DNL151 into Late Stage Parkinson's Trials

  ()
Shares of Denali Therapeutics reached a new 52-week high after the company reported plans to advance DNL151 in two separate late stage Parkinson's disease clinical studies with its partner Biogen. read more >

Fulgent Genetics' Shares Reach New 52-Week High After Posting 105% Increase in Q2 Revenue

  ()
Shares of Fulgent Genetics traded 22% higher after the company reported it posted a record $17.1 million in Q2/20 revenue and completed a record 180,513 billable tests in the quarter. read more >
News Update

Tech Firm Explains Key Feature of its Contract Tracing Solution

News Update
  ()
Loop Insights' technology lacks the adoption challenges that app-based solutions face. read more >